BioCentury
ARTICLE | Clinical News

Wave down on delay for Huntington disease readouts

April 12, 2019 9:16 PM UTC

Wave lost $7.84 (19%) to $33.91 on April 10 after it said top-line data from two Phase Ib/IIa trials of its antisense oligonucleotide therapies for Huntington disease will be delayed until year end due to slower-than-expected enrollment.

Wave Life Sciences Ltd. (NASDAQ:WVE) began in 2017 the Phase Ib/IIa PRECISION-HD1 and PRECISION-HD2 trials of WVE-120101 and WVE-120102, respectively, to treat patients with early manifest HD. At the time, the company said top-line data were expected this half (see "Wave Starts Phase Ib/IIa Testing of HD Candidates")...

BCIQ Company Profiles

Wave Life Sciences Ltd.